Justin Zelin

Q: What is Justin Zelin's success rate?

Justin Zelin currently has a success rate of 73.98644039040845.

Q: What is the average return of Justin Zelin's calls?

Their stock ratings have generated an average return of 28.484419654376634.

BTIG | Healthcare

Justin Zelin is an analyst from BTIG specializing in the Healthcare sector. Ranked #2275 out of 4771 analysts, they have issued 16 stock ratings with a success rate of 73.99% and an average return of 28.48%.

With 16 ratings to date, Justin Zelin is beginning to establish credibility in the Healthcare sector. They have achieved a success rate of 73.99% and an average return of 28.48%, highlighting promising potential as their track record develops further.

#2275

Out of 4771

Total Ratings

+73.99%

Success Rate

+28.48%

Average Return

Recent Ratings Analysis

IBRX

Buy

Jan 23, 2026

Target

$9.00

Current

$7.72

Performance

19.69%

Justin Zelin rated IBRX as Buy on Jan 23, 2026, setting a price target of 9. The call has proven timely, with shares rising 19.69% toward the price target of 9.

AVBP

Buy

Dec 10, 2025

Target

$45.00

Current

$28.70

Performance

17.86%

On Dec 10, 2025, AVBP was given a Buy rating by Justin Zelin, with a target price of 45. The stock rallied 17.86% after the rating, narrowing the gap to the target of 45 and validating the bullish stance.

SNDX

Buy

Dec 09, 2025

Target

$56.00

Current

$18.82

Performance

-3.54%

SNDX received a Buy rating from Justin Zelin on Dec 09, 2025, aiming for 56. Price action was muted, as shares hovered around 18.82 despite the bullish outlook.

MRSN

Hold

Nov 13, 2025

Target

—

Current

$29.08

Performance

6.02%

On Nov 13, 2025, Justin Zelin published a Neutral outlook on MRSN, with a target of null. The Hold call missed some of the bullish momentum as shares advanced toward null.

AAPG

Buy

Nov 10, 2025

Target

$50.00

Current

$16.67

Performance

-48.55%

Justin Zelin on Nov 10, 2025 assigned AAPG a Buy rating, with a price target of 50. The call has struggled to gain traction, with shares losing 48.55%.

TCRX

Hold

Nov 04, 2025

Target

—

Current

$0.32

Performance

-71.62%

On Nov 04, 2025, Justin Zelin reaffirmed TCRX with a Neutral rating, targeting null. The Hold stance reflected market caution that was later justified.

IPHA

Buy

Oct 29, 2025

Target

$8.00

Current

$1.88

Performance

-9.18%

IPHA was rated Buy by Justin Zelin on Oct 29, 2025, with a price objective of 8. This case shows how bullish projections can fail, with the stock now below 1.88.

IMAB

Buy

Oct 24, 2025

Target

$9.00

Current

$2.88

Performance

-31.75%

On Oct 24, 2025, Justin Zelin initiated coverage on IMAB with a Buy rating and target of 9. The Buy call has yet to be validated as shares remain 6.12 away from the target.

IDYA

Buy

Oct 21, 2025

Target

$62.00

Current

$37.45

Performance

28.25%

Justin Zelin issued a Buy recommendation for IDYA on Oct 21, 2025, price target set at 62. Investors following the Buy call captured upside momentum, with shares now at 37.45.

CAN

Buy

Oct 14, 2025

Target

$8.00

Current

$0.31

Performance

-82.85%

On Oct 14, 2025, CAN was evaluated by Justin Zelin, who gave a Buy rating and target of 8. Investors saw limited payoff as shares fell short of the 8 target.

JSPR

Buy

Sep 22, 2025

Target

$7.00

Current

$0.70

Performance

-72.41%

Justin Zelin rated JSPR as Buy on Sep 22, 2025, setting a price target of 7. The stock has underperformed, dropping 72.41% despite the bullish target of 7.

VKTX

Buy

Sep 22, 2025

Target

$125.00

Current

$32.13

Performance

22.40%

On Sep 22, 2025, VKTX was given a Buy rating by Justin Zelin, with a target price of 125. The stock rallied 22.40% after the rating, narrowing the gap to the target of 125 and validating the bullish stance.

VSTM

Buy

Sep 09, 2025

Target

$20.00

Current

$7.62

Performance

-23.19%

VSTM received a Buy rating from Justin Zelin on Sep 09, 2025, aiming for 20. The rating hasn’t played out as hoped, with the stock trading 23.19% below expectations.

ELVN

Buy

Dec 13, 2024

Target

$42.00

Current

$56.23

Performance

142.89%

On Dec 13, 2024, Justin Zelin published a Buy outlook on ELVN, with a target of 42. Shares gained 142.89%, underscoring the accuracy of the bullish outlook toward 42.

CARM

Hold

Dec 10, 2024

Target

—

Current

$0.00

Performance

-99.88%

Justin Zelin on Dec 10, 2024 assigned CARM a Neutral rating, with a price target of null. The call successfully avoided chasing as shares lost 99.88%.

PSTX

Hold

Nov 26, 2024

Target

—

Current

$9.50

Performance

1.28%

On Nov 26, 2024, Justin Zelin reaffirmed PSTX with a Neutral rating, targeting null. The neutral call matched muted market action of 1.28%.

LYRA

Hold

May 06, 2024

Target

—

Current

$0.20

Performance

-99.23%

LYRA was rated Neutral by Justin Zelin on May 06, 2024, with a price objective of null. Investors who stayed cautious avoided some of the 99.23% decline.

Frequency Asked Questions

Who is Justin Zelin?

Justin Zelin is an analyst from BTIG specializing in the Healthcare sector.

What is Justin Zelin's success rate?

Justin Zelin currently has a success rate of +73.99%.

How many ratings has Justin Zelin issued?

Justin Zelin has issued 16 stock ratings so far.

What is the average return of Justin Zelin's calls?

Their stock ratings have generated an average return of +28.48%.

What is Justin Zelin's ranking?

Justin Zelin is ranked #2275 out of 4771 analysts.

What types of ratings does Justin Zelin give?

Their ratings include Buy, Hold, and Sell recommendations, depending on the stock’s outlook.

How can I follow Justin Zelin?

You can follow Justin Zelin by clicking the "Follow Analyst" button on this page to receive updates on their stock calls.

What is the most recent rating by Justin Zelin?

Their latest rating was a Buy on IBRX issued on 2026-01-23.